Challenges in constructing genetic instruments for pharmacologic therapies

TL;DR

This paper discusses the challenges of creating genetic instruments for drug target validation due to the lack of strong genetic variants, and proposes a novel method to combine weakly associated variants into a useful genetic score.

Contribution

The paper introduces a new approach to construct genetic instruments by aggregating multiple weak variants, addressing a key challenge in pharmacogenetic research.

Findings

Proposed a method to combine weak genetic variants into a single score

Addresses the lack of large-effect variants for drug target validation

Facilitates genetic validation of pharmacologic therapies

Abstract

The genes that encode the targets of most therapies do not have rare variants with large-effect or common variants with moderate effects on the biomarker reflecting the pharmacologic action of the corresponding therapy. Therefore, providing genetic target validation for most therapies is challenging. Novel methods are being developed to combine multiple variants in the gene encoding the target of a therapy that are weakly associated with the biomarker reflecting the pharmacologic action of that therapy into a genetic score that can be used as an adequate instrumental variable. We describe one approach to solve this important problem.